Previous electrophysiological experiments using a wholecell patch-clamp technique have shown that cilnidipine can suppress N-type Ca 2 currents in addition to L-type Ca 2 channels in rat sympathetic cervical ganglion cells (10) , rat dorsal ganglion cells (11), and Xenopus oocytes that functionally expressed Ca 2 channels (12). Since N-type Ca 2 channels are located on sympathetic nerve endings, where they control catecholamine release (13) , cilnidipine could potentially affect the sympathetic regulation of the cardiovascular system. While the clinical anti-sympathetic actions of cilnidipine have been reported, as mentioned above (6) (7) (8) (9) , the neuronal Ca
Introduction
Cilnidipine is a Ca 2 channel blocker that is used for the treatment of essential hypertension and that is longer-acting than the other first-generation Ca 2 channel blockers like nifedipine (1) (2) (3) (4) (5) . Interestingly, cilnidipine has been shown to exert anti-sympathetic actions in several clinical settings. For example, cilnidipine has been reported to reduce white coat effect (6) , cold pressure stress-induced platelet aggregation (7), urinary catecholamine excretion (8) , and cardiac sympathetic overactivity measured by MIBG imaging (9) (16, 17) .
Cell Culture
The cells were cultured in 25 cm 2 flasks in standard minimal essential medium (MEM; Gibco-BRL, Grand Island, USA) supplemented with 1 non-essential amino acids (Gibco-BRL), 2 mmol/l glutamine (Gibco-BRL), 1 mmol/l sodium pyruvate (Gibco-BRL), 1 antibiotic-antimycotic (Gibco-BRL) and 10% fetal bovine serum (Equitech-Bio, Inc., Kerrville, USA) at 37°C in a humidified atmosphere of 95% air and 5% CO2. The medium was replaced every 3-4 days. After reaching 70-90% confluence, the cultures were split 1:5. For experiments involving measurements of intracellular Ca 2 concentration, cells were plated onto poly-L-lysinecoated glass coverslips. Differentiation was induced by adding 1 mmol/l dibutyryl-cAMP (Sigma, St. Louis, USA) and 2.5 µmol/l 5-bromo-2-deoxyuridine (Sigma) to the culture.
Measurement of Intracellular Ca 2 Concentration
Intracellular Ca 2 concentration in IMR-32 cells was measured using fura-2-based microfluorimetry (18) . After 8-10 days of differentiation, the cells were incubated with 5 µmol/l of fura 2-AM (Dojindo, Kumamoto, Japan) in MEM at 37°C. Thirty minutes later, the cells were washed with modified physiological salt solution (PSS; composition: NaCl 115 mmol/l, KCl 5.4 mmol/l, MgCl2 0.8 mmol/l, CaCl2 1.8 mmol/l, glucose 13.8 mmol/l, HEPES/NaOH 20 mmol/l; pH 7.4). The coverslip was mounted on the stage of microscope (TMD-2S; Nikon, Tokyo, Japan), and fluorescence images of these neurons were recorded at 6-s intervals by a video camera equipped with an Argus-50/CA system (Hamamatsu Photonics, Hamamatsu, Japan) for the control of image acquisition and display. The intensities of fluorescence at 510 nm of the cells at two alternating excitation wavelengths of 340 and 380 nm were obtained, and the ratio of the intensity of emitted fluorescence at 340 nm to that at 380 nm was calibrated to evaluate the change in intracellular Ca 2 concentration. The experiments were carried out at room temperature.
To test the response induced by activation of voltage-dependent Ca 2 channels, the cells were depolarized with 40 mmol/l KCl solution (KCl was substituted for equimolar NaCl in PSS) for 6 s, which was applied by a rapid application method termed the "Y-tube" method, as previously described (19, 20) . To assess the effects of Ca 2 channel blockers, 40 mmol/l KCl solution was applied repeatedly at 5 min intervals, and each blocker was applied 4-5 min before the application of 40 mmol/l KCl.
Drugs
Cilnidipine (molecular weight (MW) 492.5; Ajinomoto Co., Inc., Tokyo, Japan) and nifedipine (MW 346.3; Sigma) were initially dissolved in dimethylsulfoxide at a concentration of 10 mmol/l, and diluted with PSS. ω-Conotoxin GVIA (MW 3037.3; Peptide Institute, Osaka, Japan) was dissolved in PSS.
Statistics
Data are expressed as the means SEM. Student's t-test or analysis of variance (ANOVA) for repeated measures were employed for overall statistical analysis, followed by Dennett's test for statistical analyses comparing control values and experimental values. Values of p 0.05 were considered to indicate statistical significance. the application of KCl, the ratio immediately returned to the baseline value. Cilnidipine at a concentration of 3 µmol/l slightly attenuated the elevation of the ratio induced by 40 mmol/l KCl, and that of 10 µmol/l effectively suppressed the response. The reproducibility of the KCl-induced responses in the absence of drugs was confirmed in our preliminary study, where the response at the fourth stimulation was around 90% of the response to the first application of 40 mmol/l KCl (S1 in Fig. 1) .
Results
The effects of ω-conotoxin GVIA and cilnidipine are summarized in Fig. 2 . The basal values of the intensities ratio were 0.90 0.05 (n 5) in the cilnidipine-treated group and 0.95 0.04 (n 4) in the ω-conotoxin GVIA-treated group, respectively, where there were no statistically significant differences between the groups. The first application of 40 mmol/l KCl in the presence of 10 µmol/l of nifedipine increased the ratio from 0.92 0.03 to 1.51 0.03 (n 9). Cilnidipine at a concentration of 3 µmol/l suppressed the KClevoked increase in the ratio slightly but not significantly, while cilnidipine at a concentration of 10 µmol/l and ω-conotoxin GVIA at a concentration of 1 µmol/l significantly inhibited the KCl-evoked responses by 37.9 1.3% and 33.4 1.8%, respectively. Next, using nifedipine-treated IMR-32 cells, we compared the inhibitory effects of cilnidipine (10 µmol/l) on the response to 40 mmol/l KCl in the presence and absence of ω-conotoxin GVIA. As shown in Fig. 3 , the inhibitory effects of cilnidipine were significantly attenuated by 1 µmol/l of ω-conotoxin GVIA (n 6).
Discussion
The present study was designed to assess the potential utility of cilnidipine by comparing the inhibitory action of cilnidipine to that of a peptide N-type Ca 2 channel blocker, ω-conotoxin GVIA. Using human neuronal cells from the cell line IMR-32, whose Ca 2 currents consist of both L-type and Ntype components (21) , the N-type Ca 2 channel-blocking effect of cilnidipine was assessed in the presence of nifedipine to block L-type Ca 2 channels (22) . In this model, cilnidipine as well as ω-conotoxin GVIA effectively suppressed the change in the intensities ratio induced by 40 mmol/l KCl, which finding was highly similar to that in our previous study that assessed the N-type Ca 2 channel-blocking effect of cilnidipine and ω-conotoxin GVIA using rat pheochromocytoma PC12 cells (22) . Thus, it is expected that cilnidipine might be effective as a therapeutic tool to provide neuronal protection as well as its antihypertensive effects and antisympathetic actions, since blockade of N-type Ca 2 channels in the brain has been reported to reduce glutamate release and infarct volume in models of cerebral ischemia (23, 24) .
IMR-32 cells have been widely used for investigating the Ca (14), we first examined the effects of the toxin on the KCl-induced change in the ratio of the intensities of emitted fluorescence. As shown in Fig. 2 , ω-conotoxin GVIA suppressed the KCl-induced elevation of the ratio in the presence of nifedipine, suggesting that the IMR-32 cells used in this study expressed N-type in addition to L-type Ca 2 channels, as supported by earlier electrophysiological studies in which the Ca 2 currents of IMR-32 cells were effectively suppressed by ω-conotoxin GVIA (21, 25, 26) . Therefore, the current model is effective for evaluating the effects of drugs that clearly affect Ca 2 channels and that have no effect on intracellular Ca 2 release, such as cilnidipine (27) .
In this model, 10 µmol/l (4.9 µg/ml) of cilnidipine, as well as 1 µmol/l (3.0 µg/ml) of ω-conotoxin GVIA, effectively suppressed the responses to 40 mmol/l KCl in the presence of 10 µmol/l of nifedipine. Since higher concentrations of nifedipine than that used in this study have been reported to suppress N-type Ca 2 channels (10), we assessed the inhibitory action of cilnidipine in the presence of both nifedipine and ω-conotoxin GVIA to clarify the contribution of the N-type Ca 2 channel-blocking effects of cilnidipine. As shown in Fig. 3 , the effect of cilnidipine was effectively attenuated by pretreatment with ω-conotoxin GVIA in addition to nifedipine, suggesting that cilnidipine can functionally inhibit the ω-conotoxin GVIA-dependent (N-type Ca 2 channel-mediated) responses, which may be supported by the previous experimental evidence that cilnidipine could displace the [
125 I]-ω-conotoxin GVIA binding to the rat brain membrane (27) . These results indicate that cilnidipine can suppress depolarization-induced elevation of intracellular Ca 2 concentrations through N-type Ca 2 channels in human neuronal cells as well as in rodent neuronal cells (10, 11, 22) .
The concentration of cilnidipine required to suppress the N-type Ca 2 channel-mediated response in the present study was much higher than the therapeutic plasma concentrations (0.4-16.0 ng/ml) (28) . On the other hand, previous in vivo studies that measured the release of catecholamines from the canine adrenal gland, which is closely associated with the activation of N-type Ca 2 channels, have shown that infusion of 1 µg/min of cilnidipine (ca. 0.63 µg/ml in plasma) or 0.4 µg/min of ω-conotoxin GVIA (ca. 0.25 µg/ml in plasma) to the nutrient artery equipotently inhibited the release of catecholamines (29, 30) . Thus, relatively higher concentrations of drugs may be required to suppress N-type Ca 2 channel-associated responses in the current model using IMR-32 cells than are required in vivo. Furthermore, in an in vivo rat brain ischemia model, effective plasma concentrations of the selective N-type Ca 2 channel blocker ω-conotoxin MVIIA (SNX-111), which has a similar potency to ω-conotoxin GVIA (31), have been reported to be around 15 ng/ml (32) . Thus, the current results obtained using 10 µmol/l of cilnidipine should provide important information for prospective applications of the drug, although additional studies in the experimental and clinical states will be needed to confirm our findings.
In conclusion, cilnidipine suppressed the depolarizationevoked elevation of intracellular Ca channel-blocking activity, as it has previously been shown to do in pheochromocytoma cells (22) . Thus, cilnidipine might be applied as a prospective therapeutic tool to provide neuronal protection as well as its antihypertensive effects and anti-sympathetic actions.
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